Choose the milestones that matter
Emerging biopharma companies cannot control funding sentiment or policy shifts, but they can clarify their priorities. Rank programs against scientific risk, unmet need, regulatory prospects, strategic fit, and the cost of reaching the next meaningful milestone.
Identify credible milestones over the next 12–18 months and create rigorous decision gates. Smaller, fundable phases can give investors a clearer view of progress and stop weak programs from consuming scarce runway.
Strengthen execution around those choices
Map the timeline, expose dependencies, and monitor internal and outsourced work consistently. Improve workflows and vendor management while maintaining transparent relationships with development partners.
Communicate the plan and its uncertainty to employees. In small organizations, each person’s contribution has disproportionate impact. A clear link between individual work and company outcomes helps teams stay engaged when external conditions are difficult. Consistency, learning, and disciplined choices create a stronger foundation than waiting for the market to normalize.